来那度胺在MM外的应用sent

(N = 104)Р中位年龄, 岁(范围)Р64.5 (32–81)Р男性, n (%)Р72 (69.2)РRAI 分期, n (%)Р低危Р8 (7.7)Р中危Р13 (12.5)Р高危Р17 (16.3)Р 分期 n (%)РAР10 (9.6)РBР29 (27.9)РCР25 (24.0)РCLL-009 (Wendtner) :?试验结果Р24.3% 的患者剂量升至25mg最高剂量?56.3% 的患者发生≥ 1 次的剂量下调?治疗中止的主要原因:AEs (n=35) 和 PD (n=24)Р10РWendtner C, Hallek M, Fraser G, et al. Updated Interim Results of the Safety and Efficacy of Different 来那度胺 Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). Poster presented at: Annual Meeting and Exposition of the American Society of Hematology 2012; December 8-11; Atlanta, GA.Р治疗暴露Р所有患者Р5 mg?剂量组Р10 mg?剂量组Р15 mg ?剂量组Р平均剂量, mg/dayР11.6Р8.8Р11.7Р14.3Р治疗持续时间, 周Р32.8Р30.2Р35.8Р32.6Р治疗中止, n (%)Р79 (76.0)Р24 (70.6)Р25 (71.4)Р30 (85.7)РCLL-009 (Wendtner) :?试验结果